La chaîne d'options affiche les données clés des options sur actions de Regencell Bioscience à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Regencell Bioscience..

Regencell Bioscience (NASDAQ:RGC) Stock, Chaîne d'Options

Regal Entertainment Group Class A Common Stock

Regal Entertainment

Regal Entertainment Group

NYSE

Regencell Bioscience

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience Holdings Ltd

Relevant Gold Corp

RGC Resources Inc

As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Regencell Bioscience Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>)</h3>
<ul class="wp-block-list">
<li>Regencell Bioscience's 38-for-one forward stock split officially took effect on Monday. The split, announced at the beginning of June and distributed on June 13, gave shareholders 37 additional shares for each one they already owned. The stock began trading on a split-adjusted basis on Monday. The company stated that the goal of the split was to improve liquidity and make its shares more accessible to investors. The company's stock jumped around 548% over the past month and has a <a href="https://www.benzinga.com/quote/RGC">52-week high of $83.60</a>.</li>
<li>RSI Value: 94&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>RGC Price Action: Shares of Regencell Bioscience gained 276.2% to close at $60.00 on Monday.</li>
<li>Edge Stock Ratings: 91.92 Momentum score with Value at 93.51.</li>
</ul>
<h3 class="wp-block-heading">Verve Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)</h3>
<ul class="wp-block-list">
<li>On May 14, Verve Therapeutics reported a year-over-year increase for first-quarter EPS results. &#8220;2025 is off to a strong start with both clinical and regulatory progress. Last month, we reported exciting initial data from the Heart-2 clinical trial, which demonstrated that a single infusion of VERVE-102, a base editing medicine targeting PCSK9, was well-tolerated and led to compelling, dose-dependent reductions in LDL-C. These data, along with ongoing durability data of up to two years from our Heart-1 clinical trial, suggest a product profile that could fundamentally transform the journey for patients living with cardiovascular disease from decades of chronic care to a one dose future,&#8221; said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. The company's stock gained around 43% over the past month and<a href="https://www.benzinga.com/quote/VERV"> has a 52-week high</a> of $9.30.</li>
<li>RSI Value: 88.1</li>
<li>VERV Price Action: Shares of Verve Therapeutics rose 1.8% to close at $6.27 on Monday.</li>
</ul>
<h3 class="wp-block-heading">SAGE Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>)</h3>
<ul class="wp-block-list">
<li>On June 16, Supernus Pharmaceuticals agreed to acquire Sage Therapeutics for $12.00 per share in cash, or an aggregate of up to approximately $795 million. The deal consideration includes $8.50 per share in cash (or an aggregate of approximately $561 million) plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million). The company's stock gained around 32% over the past five days and has a <a href="https://www.benzinga.com/quote/SAGE">52-week high </a>of $13.46.</li>
<li>RSI Value: 86.2</li>
<li>SAGE Price Action: Shares of SAGE Therapeutics gained 35.4% to close at $9.07 on Monday.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">stocks in the sector and see how they compare.</a>
Read This Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45948533/top-2-financial-stocks-that-may-plunge-in-q2"> Top 2 Financial Stocks That May Plunge in Q2</a></li>
</ul>

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

SAGE

VERV

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

Shares of Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) rose sharply in today's pre-market trading after the company reported mixed results <a href="https://www.benzinga.com/quote/LEN/earnings">for the second quarter</a>.
Lennar reported quarterly earnings of $1.90 per share, which missed the Street estimate of $1.94. Quarterly revenue of $8.38 billion beat the analyst consensus estimate of $8.16 billion.
Lennar shares jumped 2.3% to $111.97 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>XCF Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFX#NASDAQ">SAFX</a>) surged 113.1% to $4.71 in pre-market trading after dipping around 37% on Monday. XCF Global announced the appointment of new board of directors following business combination.</li>
<li>Salarius Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares jumped 110.9% to $1.33 in pre-market trading after the company disclosed it received an extension from the Nasdaq to regain compliance.</li>
<li>Verve Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) jumped 84.1% to $11.54 in pre-market trading.</li>
<li>Jianzhi Education Technology Group Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) gained 43% to $4.09 in pre-market trading after gaining 6% on Monday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) rose 43.1% to $85.86 in pre-market trading. Regencell Bioscience shares jumped 276% on Monday after the company's 38-for-one forward stock split officially took effect.</li>
<li>Trident Digital Tech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) rose 40.2% to $0.3428 in pre-market trading after gaining over 15% on Monday. Trident Digital Tech, last week, announced an initiative to raise up to $500 million to establish a corporate XRP treasury.</li>
<li>BGSF, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) climbed 39.9% to $5.65 in pre-market trading after the company agreed to sell Professional Division to INSPYR Solutions for $99 million in an all-cash deal.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) surged 8.8% to $13.18 in pre-market trading after dipping 16% on Monday.</li>
<li>AIRO Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) gained 8.7% to $33.69 in pre-market trading after surging 29% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares tumbled 27.4% to $7.00 in pre-market trading. Jefferies, last week, downgraded the stock from Hold to Underperform and lowered its price target from $6 to $5.</li>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) shares fell 24.9% to $0.1550 in pre-market trading after the company announced intention to file under the Bankruptcy and Insolvency Act in Canada.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) dipped 21.5% to $18.79 in pre-market trading. Barclays analyst Christine Cho, last week, maintained SolarEdge Technologies with an Underweight and raised the price target from $11 to $12.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) declined 16.7% to $38.28 in pre-market trading.</li>
<li>CDT Environmental Technology Investment Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) dipped 15.4% to $1.16 in pre-market trading.</li>
<li>Smart Powerr Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREG#NASDAQ">CREG</a>) declined 15% to $0.3060 in pre-market trading after dipping 38% on Monday.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) fell 11.4% to $0.2880 in pre-market trading after tumbling 7% on Monday. Adial Pharmaceuticals submitted the required briefing package to the FDA for the upcoming end of Phase 2 meeting.</li>
<li>Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) fell 10.1% to $18.48 in pre-market trading after the company announced a $200 million common stock offering.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) declined 10.1% to $157.00 in pre-market trading. Jefferies analyst Julien Dumoulin-Smith, last week, upgraded First Solar from Hold to Buy and raised the price target from $157 to $192.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) fell 9.2% to $7.23 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45948410/5-stocks-in-the-spotlight-from-wall-streets-most-accurate-analysts-last-week-5">5 Stocks In The Spotlight From Wall Street&#8217;s Most Accurate Analysts Last Week</a> </li>
</ul>
Photo via Shutterstock

Movers

ADIL

AIRO

ARRY

BGSF

CDTG

CREG

ENPH

FSLR

LDTC

LIMN

SAFX

SEDG

SLRX

TDTH

Why Lennar Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Regencell Bioscience Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares are soaring Monday after the company&#8217;s 38-for-one forward stock <a href="https://regencellbioscience.com/regencell-bioscience-holdings-limited-announces-forward-stock-split/">split officially took effect</a>.
What To Know: The split, announced at the beginning of June and distributed on June 13, gave shareholders 37 additional shares for each one they already owned. The stock began trading on a split-adjusted basis on Monday. The company stated that the goal of the split was to improve liquidity and make its shares more accessible to investors.
Regencell is an early-stage bioscience company based in Hong Kong. The company focuses on developing traditional Chinese medicine treatments for neurological disorders, specifically ADHD and autism spectrum disorder.
The stock split doesn't alter the company's fundamentals or financial outlook. The sharp spike in the company&#8217;s share price likely reflects speculative interest following the split. Investors may be reacting to the lower price per share post-split, which can drive short-term volume and volatility.
<h3 class="wp-block-heading">How To Buy RGC Stock</h3>
By now you're likely curious about how to participate in the market for Regencell Bioscience &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
RGC Price Action: Regencell Bioscience shares were up 276.5% at $59.21 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45952716/stock-market-today-sp500-rises-iran-israel-nasdaq-near-record-highs">Wall Street Roars Back As Iran Signals De-Escalation: Nasdaq 100 Nears All-Time High </a></li>
</ul>
Image via Shutterstock.

Stock Split

What's Going On With Regencell Bioscience Stock Today?

WIIM

Regencell Bioscience shares are trading higher. The company effected a 38-for-1 forward stock split.

Regencell Bioscience Shares Resume Trade

Regencell Bioscience Shares Halted On Circuit Breaker To The Upside, Stock Now Up 328.4%

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 400 points on Monday.
Following the market opening Monday, the Dow traded up 1.02% to 42,629.20 while the NASDAQ climbed 1.32% to 19,663.87. The S&amp;P 500 also rose, gaining, 1.03% to 6,038.26.
Check This Out: <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45948648/this-boston-scientific-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday">This Boston Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday</a>
Leading and Lagging Sectors Information technology shares jumped by 1.5% on Monday.
In trading on Monday, energy stocks fell by 0.5%.
Top Headline
The New York Empire State Manufacturing Index dipped to a reading of -16 in June compared to May's reading of -9.2, and also down from market estimates of -5.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares shot up 238% to $53.91 following effect of a 38-for-1 forward stock split.</li>
<li>Shares of SRM Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) got a boost, surging 210% to $4.5250 after the company entered a securities purchase agreement with a private investor for a $100 million equity investment, which it will use to initiate a TRON token treasury strategy.</li>
<li>Dawson Geophysical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWSN#NASDAQ">DWSN</a>) shares were also up, gaining 174% to $3.7492.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Robin Energy Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) shares dropped 58% to $5.87. Robin Energy announced pricing of $5.1 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) were down 48% to $18.83 after the company suspended ELEVIDYS shipments and paused the ENVISION trial following a second fatal liver failure in non-ambulatory Duchenne patients.</li>
<li>Top Ships Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPS#NASDAQ">TOPS</a>) was down, falling 47% to $5.09.</li>
</ul>
Commodities In commodity news, oil traded down 3.3% to $70.54 while gold traded down 1.1% at $3,415.70.
Silver traded up 0.1% to $36.395 on Monday, while copper rose 0.1% to $4.8190.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.3%, while Spain's IBEX 35 Index rose 1.2%. London's FTSE 100 gained 0.334%, Germany's DAX 40 rose 0.6% and France's CAC 40 climbed 0.8% during the session.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei gaining 1.26%, Hong Kong's Hang Seng Index rising 0.70%, China's Shanghai Composite rising 0.35% and India's BSE Sensex climbing 0.84%.
Economics
The New York Empire State Manufacturing Index dipped to a reading of -16 in June compared to May's reading of -9.2, and also down from market estimates of -5.5.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45946608/top-3-materials-stocks-that-could-blast-off-this-month-3">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

DWSN

RBNE

SRPT

TOPS

US Stocks Higher; Dow Jumps Over 400 Points

Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/INCY">pre-market trading</a>.
QIAGEN and Incyte disclosed a precision medicine collaboration to develop companion diagnostics for patients with mutant CALR-expressing Myeloproliferative Neoplasms (MPNs).
Incyte shares jumped 9.6% to $74.25 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>TMD Energy Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#NYSE">TMDE</a>) surged 203% to $3.85 in pre-market trading after gaining over 75% on Friday.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares jumped 169.6% to $43.00 in pre-market trading after dipping 97% on Friday.</li>
<li>Battalion Oil Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BATL#NASDAQ">BATL</a>) jumped 166% to $4.37 in pre-market trading after gaining 15% on Friday.</li>
<li>OceanPal Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) gained 91.9% to $3.09 in pre-market trading after gaining 123% on Friday.</li>
<li>K Wave Media Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWM#NASDAQ">KWM</a>) rose 69.3% to $4.91 in pre-market trading after tumbling over 50% on Friday.</li>
<li>New Era Helium, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEHC#NASDAQ">NEHC</a>) climbed 51.1% to $0.8206 in pre-market trading after declining around 10% on Friday. New Era Helium, last week, announced that its joint venture with Sharon AI, Texas Critical Data Centers, is in active discussions with enterprises to anchor its planned AI infrastructure buildout in Texas.</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) rose 47.8% to $24.83 in pre-market trading after falling 7% on Friday.</li>
<li>AIRO Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRO#NASDAQ">AIRO</a>) surged 30.2% to $31.25 in pre-market trading after jumping 140% on Friday. AIRO Group priced its $60 million initial public offering of 6 million common shares at $10 per share.</li>
<li>IperionX Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPX#NASDAQ">IPX</a>) gained 13% to $29.31 in pre-market trading after falling 5% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares tumbled 31.4% to $24.86 in pre-market trading after the company suspended ELEVIDYS shipments and paused ENVISION trial after second fatal liver failure in non-ambulatory Duchenne patients.</li>
<li>Dragonfly Energy Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) dipped 26.5% to $0.2228 in pre-market trading after falling 10% on Friday.</li>
<li>KULR Technology Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NYSE">KULR</a>) shares fell 21.9% to $0.8980 in pre-market trading after the company reported a 1-for-8 reverse stock split.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) declined 17% to $0.7141 in pre-market trading after dipping 22% on Friday.</li>
<li>Greenlane Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) fell 15.9% to $0.0085 in pre-market trading after tumbling 34% on Friday.</li>
<li>Gold Royalty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROY#NYSE">GROY</a>) dipped 14.7% to $1.95 in pre-market trading. Canaccord Genuity, on June 11, initiated a Buy rating on the stock and announced a $3 price target.</li>
<li>Catheter Precision, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#NYSE">VTAK</a>) declined 9.8% to $0.3150 in pre-market trading after dipping 15% on Friday.</li>
<li>Solid Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) fell 8% to $4.15 in pre-market trading. JMP Securities, on June 6, reiterated its Market Outperform rating on the stock and maintained a $15 price target.</li>
<li>FiEE, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) declined 7% to $2.47 in pre-market trading.</li>
<li>Omada Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) fell 5.4% to $16.18 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a> </li>
</ul>
Photo via Shutterstock

BATL

DFLI

GNLN

GROY

INCY

KULR

MINM

MLGO

NEHC

OMDA

SATS

SLDB

TMDE

VTAK

Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket

Regencell Bioscience Shares Trading Premarket Following Effect Of A 38-For-1 Forward Stock Split

U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Friday.
Shares of Quanex Building Products Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) rose sharply during Friday's session after the company reported better-than-expected second-quarter <a href="https://www.benzinga.com/quote/NX">financial results</a>.
Quanex Building reported quarterly earnings of 60 cents per share which beat the analyst consensus estimate of 47 cents per share. The company reported quarterly sales of $452.50 million which beat the analyst consensus estimate of $439.30 million.
Quanex Building Products shares jumped 23.4% to $21.10 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Tango Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) shares jumped 27% to $4.4776.</li>
<li>Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) jumped 17.7% to $97.48 after gaining 168% on Thursday.</li>
<li>The Generation Essentials Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGE#NYSE">TGE</a>) rose 17% to $11.76.</li>
<li>Manchester United plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) gained 15.2% to $15.94 after the company reported better-than-expected third-quarter sales results.</li>
<li>Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) rose 15.8% to $8.48.</li>
<li>Taseko Mines Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGB#NYSE">TGB</a>) gained 13.5% to $2.9450.</li>
<li>Cogent Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) surged 13.2% to $6.78.</li>
<li>Byrna Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) rose 12.7% to $29.96. Byrna Technologies announced preliminary fiscal second quarter record revenues of $28.5 million.</li>
<li>QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) rose 11.7% to $18.74. Wolfe Research analyst Trevor Allinson initiated coverage on QXO with an Outperform rating and announced a price target of $44.</li>
<li>TSS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) gained 10% to $18.70.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) climbed 9.8% to $14.05.</li>
<li>Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) rose 9.3% to $34.42.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) climbed 9.1% to $147.34.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) rose 8.2% to $17.78.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 7.7% to $689.00.</li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) gained 6.6% to $198.94. AeroVironment will report its financial results for the fourth quarter after the market closes on Tuesday, June 24.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>
Photo via Shutterstock

APLD

AVAV

BYRN

COGT

CRCL

CRWV

LEGN

MANU

QBTS

RCAT

TNGX

TSSI

Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock rose 55.3% to $2.36 during Friday's pre-market session. The market value of their outstanding shares is at $3.5 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares increased by 50.62% to $3.6. The company's market cap stands at $5.1 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock rose 39.79% to $4.39. The market value of their outstanding shares is at $12.6 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 23.2% to $770.0. The company's market cap stands at $10.0 billion. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock moved upwards by 17.54% to $1.34. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock moved upwards by 14.12% to $1.45. The market value of their outstanding shares is at $3.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) stock decreased by 29.8% to $21.5 during Friday's pre-market session. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares declined by 22.37% to $1.18. The company's market cap stands at $121.5 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares fell 17.12% to $20.39. The company's market cap stands at $530.4 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares declined by 13.24% to $2.82. The company's market cap stands at $2.6 million. </li>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) shares fell 11.01% to $0.48. The market value of their outstanding shares is at $14.8 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares fell 10.44% to $2.06. The company's market cap stands at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

ARAY

BJDX

DRRX

EYEN

HSDT

NIVF

SCNI

VERA

VERO

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares moved upwards by 91.2% to $24.3 during Thursday's pre-market session. The company's market cap stands at $649.1 million. </li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) shares rose 26.65% to $0.85. The company's market cap stands at $52.1 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares increased by 23.69% to $0.71. The company's market cap stands at $5.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock rose 22.2% to $770.0. The market value of their outstanding shares is at $10.0 billion. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock rose 16.84% to $6.45. The company's market cap stands at $2.7 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) shares increased by 12.98% to $0.65. The company's market cap stands at $58.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares fell 76.7% to $0.76 during Thursday's pre-market session. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock fell 37.29% to $1.48. The company's market cap stands at $48.3 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares declined by 11.8% to $0.46. The company's market cap stands at $7.7 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares fell 11.51% to $3.0. The market value of their outstanding shares is at $78.2 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares fell 9.1% to $0.3. The market value of their outstanding shares is at $11.7 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares fell 8.98% to $0.28. The market value of their outstanding shares is at $17.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APDN

ATHA

CBUS

CGTX

CNTX

KAPA

KRON

SILO

SNTI

12 Health Care Stocks Moving In Thursday's Pre-Market Session

U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Wednesday.
Shares of Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter financial results. Also, multiple firms raised their respective <a href="https://www.benzinga.com/quote/GWRE/earnings">price targets on the stock</a>.
Guidewire Software reported quarterly earnings of 88 cents per share which beat the analyst consensus estimate of 47 cents per share. The company reported quarterly sales of $293.51 million which beat the analyst consensus estimate of $286.39 million.
Guidewire Software shares jumped 19.1% to $259.83 on Wednesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Ctrl Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) shares jumped 54% to $50.67.</li>
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) gained 27.8% to $8.71 after the company raised its FY26 adjusted EPS guidance above estimates. Also, Needham reiterated a Buy rating on the stock.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) rose 22.7% to $12.58.</li>
<li>REV Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) rose 16.7% to $43.45 after the company reported better-than-expected second-quarter financial results and raised its FY25 sales guidance.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.8% to $36.05.</li>
<li>Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) rose 15.2% to $17.05 after the company announced it will advance lunar and martian manufacturing technology after receiving a NASA critical design review pass.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) jumped 15.2% to $3.1800.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) gained 13.5% to $6.74. Navitas Semiconductor recently announced it has entered a partnership with BrightLoop for hydrogen fuel-cell charge.</li>
<li>STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) gained 11.1% to $28.50.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 10% to $670.00. Regencell Bioscience recently announced a 38-for-1 forward stock split.</li>
<li>HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) gained 9.2% to $113.30 after the company reported better-than-expected first-quarter adjusted EPS results and raised its FY26 guidance. Also, multiple firms raised their respective price targets on the stock.</li>
<li>KB Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) rose 8.6% to $79.70.</li>
<li>Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) gained 7.5% to $83.47 after the company raised its fourth-quarter guidance. Additionally, Rosenblatt raised its price target on the stock from $94 to $105.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) rose 7.5% to $3.7997.</li>
</ul>
Now Read This<a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">: </a>
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Photo via Shutterstock

GWRE

LITE

MCTR

NVTS

REVG

YEXT

ZLAB

Guidewire Software Posts Upbeat Q3 Results, Joins Yext, REV Group And Other Big Stocks Moving Higher On Wednesday

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 75.7% to $6.57 during Wednesday's pre-market session. The company's market cap stands at $6.6 million. </li>
<li>Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) stock increased by 40.45% to $4.34. The company's market cap stands at $38.4 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 26.41% to $770.0. The market value of their outstanding shares is at $10.0 billion. </li>
<li>Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) shares increased by 23.69% to $4.49. The company's market cap stands at $144.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock moved upwards by 20.27% to $3.5. The company's market cap stands at $5.1 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock increased by 13.9% to $0.57. The market value of their outstanding shares is at $14.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock fell 22.7% to $2.86 during Wednesday's pre-market session. The company's market cap stands at $2.1 million. </li>
<li>Kalaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLRS#NASDAQ">KLRS</a>) shares declined by 18.51% to $2.51. The company's market cap stands at $46.9 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 16.39% to $0.05. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock fell 14.35% to $4.36. The company's market cap stands at $81.9 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) shares declined by 13.81% to $0.86. The market value of their outstanding shares is at $14.3 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares decreased by 13.34% to $5.85. The company's market cap stands at $4.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMGL

DARE

KLRS

MHUA

NCNA

RSLS

SGMT

STSS

SXTP

VYNE

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Regencell Bioscience shares are trading lower after the company announced a 38-for-1 forward stock split.

Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) (the "Company"), today announced that its board of directors approved a 38-for-one forward stock split to be paid in the form of a stock bonus. Each shareholder of the Company of record at the close of business on June 12, 2025 will receive 37 additional shares for every share held on the record date. The Company expects the additional shares will be distributed on June 13, 2025. Subject to the final approval by the Nasdaq Capital Market, trading is expected to begin on a post-stock split adjusted basis at market open on June 16, 2025.
The forward stock split is intended to enhance liquidity in the market for the Company's ordinary shares and make the shares more accessible to investors.
Following the split, the Company's outstanding shares will be increased at the ratio of the forward stock split. The Company's authorized share capital and the share par value will remain unchanged.
There will be no change to the Company's name, CUSIP or its current trading symbol in connection with the forward stock split.
No action is required by shareholders in connection with the forward stock split. Shareholders who hold their shares through a brokerage account will have their shares automatically adjusted to reflect the forward stock split. Registered shareholders will receive their additional shares through the Company's transfer agent.

Reported Earlier: Regencell Bioscience Announces 38-For-1 Forward Stock Split, With Share Distribution On June 13, 2025 And Post-Split Trading Set For June 16, 2025

<h3>Gainers</h3>
<ul>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares moved upwards by 463.3% to $27.77 during Monday's pre-market session. The market value of their outstanding shares is at $36.8 million. </li>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) shares increased by 62.58% to $30.81. The company's market cap stands at $1.9 billion. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock increased by 39.8% to $0.4. The company's market cap stands at $2.3 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock increased by 39.09% to $8.46. The market value of their outstanding shares is at $158.8 million. </li>
<li>Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) stock rose 34.95% to $40.0. The company's market cap stands at $2.6 billion. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares moved upwards by 30.9% to $35.28. The company's market cap stands at $231.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Telomir Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) stock declined by 24.9% to $1.46 during Monday's pre-market session. The company's market cap stands at $43.4 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock decreased by 21.98% to $0.83. The company's market cap stands at $43.2 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares fell 19.27% to $3.96. The market value of their outstanding shares is at $2.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock fell 16.21% to $0.87. The company's market cap stands at $7.5 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock fell 12.21% to $770.0. The market value of their outstanding shares is at $10.0 billion. </li>
<li>Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) shares fell 10.8% to $1.24. The company's market cap stands at $125.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KYMR

LUCD

LYRA

PSTV

SLXN

TELO

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares rose 171.6% to $2.83 during Friday's regular session. The market value of their outstanding shares is at $53.0 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock moved upwards by 50.92% to $5.72. The market value of their outstanding shares is at $21.2 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares moved upwards by 39.78% to $2.78. The company's market cap stands at $48.7 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 23.48% to $915.0. The company's market cap stands at $11.9 billion. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) shares rose 23.0% to $2.62. The company's market cap stands at $146.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 20.47% to $1.74. The market value of their outstanding shares is at $3.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) stock fell 29.5% to $3.2 during Friday's regular session. The market value of their outstanding shares is at $36.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares declined by 29.48% to $18.48. The market value of their outstanding shares is at $13.7 billion. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) stock fell 28.41% to $3.9. The market value of their outstanding shares is at $2.8 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares decreased by 27.38% to $0.49. The market value of their outstanding shares is at $21.5 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) stock declined by 24.29% to $0.46. The market value of their outstanding shares is at $22.5 million. </li>
<li>EXoZymes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) shares decreased by 21.01% to $10.98. The company's market cap stands at $91.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALZN

ASBP

BLRX

CLGN

EXOZ

HBIO

IMNN

SMMT

SPRO

12 Health Care Stocks Moving In Friday's Intraday Session

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday.
Shares of Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45695903/ulta-stock-is-rising-friday-whats-going-on">raised guidance</a>.
Ulta reported earnings per share of $6.70, beating the consensus estimate of $5.77. In addition, the company reported sales of $2.85 billion, beating the consensus estimate of $2.79 billion, and representing a 4.5% year-over-year gain.
Ulta Beauty shares jumped 11.2% to $469.27 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>LiveWire Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVWR#NASDAQ">LVWR</a>) shares jumped 54.5% to $4.43.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 22.1% to $905.00.</li>
<li>Zhengye Biotechnology Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) rose 16.1% to $9.50.</li>
<li>TSS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) gained 12.5% to $13.77.</li>
<li>Universal Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UVV#NYSE">UVV</a>) rose 11.4% to $66.16 following quarterly results.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) gained 11.3% to $4.7950.</li>
<li>NGL Energy Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGL#NYSE">NGL</a>) surged 11% to $3.5750 following fourth-quarter results.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) gained 10.7% to $26.32 after Jefferies upgraded the stock from hold to buy and raised its price target from $22 to $29.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) rose 10.5% to $18.95.</li>
<li>GATX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATX#NYSE">GATX</a>) gained 9.9% to $160.98 after Wells Fargo agreed to sell its Rail Leasing Business to the company for $4.4 billion through a joint purchase with Brookfield Infrastructure Partners.</li>
<li>BRP Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) surged 7.7% to $43.70 after TD Securities upgraded the stock from Hold to Buy.</li>
<li>Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) rose 7.7% to $270.37 after better-than-expected earnings</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45691209/top-3-materials-stocks-that-could-blast-off-this-month-2">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

DOOO

GATX

LVWR

PONY

SHLS

ULTA

ZYBT

Ulta Beauty Posts Upbeat Results, Joins Unity Software, GATX And Other Big Stocks Moving Higher On Friday

<h3>Gainers</h3>
<ul>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) stock moved upwards by 125.2% to $5.16 during Thursday's regular session. The company's market cap stands at $22.0 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares increased by 115.65% to $0.61. The market value of their outstanding shares is at $27.1 million. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares increased by 86.29% to $6.18. The company's market cap stands at $4.5 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares rose 64.65% to $0.01. The market value of their outstanding shares is at $3.9 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) shares moved upwards by 55.53% to $1.39. The company's market cap stands at $19.9 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 54.8% to $805.0. The market value of their outstanding shares is at $10.4 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock declined by 54.6% to $0.88 during Thursday's regular session. </li>
<li>Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) shares decreased by 28.59% to $0.65. The company's market cap stands at $62.2 million. </li>
<li>Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) stock decreased by 26.25% to $7.12. The market value of their outstanding shares is at $738.0 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock declined by 24.96% to $4.39. The company's market cap stands at $119.8 million. </li>
<li>EXoZymes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) stock decreased by 21.58% to $10.98. The company's market cap stands at $91.8 million. </li>
<li>Aspire Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares fell 16.91% to $0.59. The company's market cap stands at $29.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Regencell Bioscience

Regencell Bioscience (RGC) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL